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Resident memory
Although T-cell memory has been thought to reside in the blood 
and lymph nodes, recent advances have suggested that resident 
memory T (TRM) cells in peripheral tissues provide immune 
memory. Jiang and colleagues recently used a mouse model 
of vaccinia virus (VACV) skin infection to explore this notion. 
VACV skin infection resulted in the generation of long-lived cir-
culating CD8+ TRM cells that reside in the skin. These cells were 
superior to central memory T (TCM) cells in protecting against 
subsequent VACV infection. In response to infection, TCM cells 
were detected in the blood and lymph nodes, whereas TRM cells 
remained in the skin. In addition, TRM cells were found far from 
the infection site and, in fact, were found to populate the entire 
skin surface. These studies demonstrate that TRM cells accumu-
late at the infection site as well as at distant sites and provide 
broad and long-lived protective T-cell immunity against viral 
infection. (Nature 483:227–31, 2012) Selected by S. Yuspa
Distant effects
Localized radiotherapy induces abscopal effects, which involve 
regression of metastatic cancer at sites distant from the irradi-
ated site, in melanoma, lymphoma, and renal cell carcinoma. 
Although the mechanism of this effect is unknown, several 
lines of evidence point to the immunological response. Postow 
and colleagues recently reported a case of the abscopal effect 
in a melanoma patient treated with radiotherapy and ipilim-
umab, a monoclonal antibody that inhibits a T-cell check point. 
Although ipilimumab improves overall survival in advanced 
melanoma, the response rate is still only 10–15%; thus, this 
treatment is commonly paired with additional therapies. The 
female patient in this study showed a systemic response to 
localized radiotherapy following disease progression while 
being treated with ipilimumab. The 19-month interval between 
drug treatment initiation and disease response following 
radiotherapy supports an abscopal effect. Furthermore, tumor 
regression in concert with the identified antibody response is in 
agreement with an immunological cause for abscopal effects. 
(N Engl J Med 366:925–31, 2012) Selected by L. Beck
New gene implicated in repair
The gene mutated in autosomal recessive UV-sensitive syn-
drome (UVSS) A was unknown, although mutations in 
ERCC8 and ERCC6 have been implicated in other classes 
of UVSS. In these patients, mutations confer photosensitiv-
ity and defects in transcription-coupled repair (TCR), a special 
nucleotide excision repair pathway that is important for the 
repair of UV-induced DNA damage. Zhang and colleagues 
utilized microcell-mediated chromosome transfer in mouse 
cells to clone the gene mutated in UVSS, the mouse equiva-
lent of human KIAA1530 (which was renamed UVSSA for 
UV-stimulated scaffold protein A). Further investigations of the 
role of this factor in TCR revealed that UVSSA interacts with the 
ubiquitin-specific processing protease 7, which was implicated 
in TCR, and transiently binds ERCC8 and that these factors are 
recruited to sites of RNA Pol II and ERCC6 in the UV-damaged 
chromatin fraction. In addition, UVSSA functions in the stabili-
zation of ERCC6 in TCR and is ultimately required for excision 
of DNA damage during this process. (Nat Genet doi.10.1038/
ng.2228, 2012) Selected by M. Amagai
Control of the mucosa
At the mucosal interface, potent immune defenses and regu-
lation of inflammatory responses are balanced to fight infec-
tion while preventing tissue damage. Regulatory T cells (Tregs), 
which function at this interface, are generated in both the thy-
mus (tTreg) and the periphery (induced Treg (iTreg)); however, 
the roles of these cells in immune homeostasis and microbial 
defense are unknown. Therefore, Josefowicz and colleagues 
examined these regulatory cells in mice deficient for CNS1, 
a factor critical for induction of Treg differentiation. In these 
mice, iTreg differentiation was affected specifically. The mice 
also developed T helper type 2 (Th2)-type pathologies at the 
mucosal sites in the gastrointestinal tract and lungs. This iTreg 
alteration also changed the microbial communities in the gut. 
Furthermore, these studies revealed that tTregs were sufficient 
for control of most immune responses to self-antigens and sug-
gested that iTregs play a nonredundant role in control of muco-
sal allergic Th2 inflammation. (Nature 482:395–99, 2012) 
Selected by M. Amagai
Green light for ixekizumab
Because psoriasis pathology stems, at least in part, from T helper 
type 17 (Th17)-cell secretion of proinflammatory cytokines such 
as interleukin (IL)-17A, specific inhibition of IL-17A is a novel 
targeted approach for psoriasis treatment. In a phase II, double-
blind, placebo-controlled trial involving 142 patients, Leonardi 
and colleagues evaluated the safety and efficacy of the human-
ized IgG4 monoclonal antibody ixekizumab, which neutralizes 
IL-17A. Significant and dose-dependent increases in numbers of 
ixekizumab-treated patients who had psoriasis area–and–sever-
ity index (PASI) scores reduced by at least 75, 90, or 100% were 
observed at 12 weeks and sustained through the 20-week study. 
In addition, these responses were rapid, with observation of sig-
nificant differences in PASI scores between treatment and place-
bo groups as early as after one week. No serious adverse events 
were noted, underscoring the safety of this treatment. Moreover, 
patients with hard-to-treat scalp or nail psoriasis also benefited 
from treatment. Thus, inhibition of IL-17 may be an effective tar-
geted therapy for patients with moderate to severe plaque pso-
riasis. (N Engl J Med 366:1190–9, 2012) Selected by B. Gilchrest
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